Cargando…

Selection of hepatitis C virus resistant to ribavirin

BACKGROUND: Given the side effects associated with intravenous injections of interferon, an interferon-free regimen for the treatment of HCV infections is highly desirable. Recently published clinical studies show that interferon-free combination therapies containing ribavirin are efficacious, sugge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feigelstock, Dino A, Mihalik, Kathleen B, Feinstone, Stephen M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163560/ https://www.ncbi.nlm.nih.gov/pubmed/21843317 http://dx.doi.org/10.1186/1743-422X-8-402

Ejemplares similares

Sensitivity of a Ribavirin Resistant Mutant of Hepatitis C Virus to Other Antiviral Drugs
por: Mihalik, Kathleen B., et al.
Publicado: (2013)

Increased susceptibility of Huh7 cells to HCV replication does not require mutations in RIG-I
por: Feigelstock, Dino A, et al.
Publicado: (2010)

Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma
por: Zhang, Pei, et al.
Publicado: (2007)

Persistent Growth of a Human Plasma-Derived Hepatitis C Virus Genotype 1b Isolate in Cell Culture
por: Silberstein, Erica, et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Chimeric Mouse Model for the Infection of Hepatitis B and C Viruses
por: Tesfaye, Abeba, et al.
Publicado: (2013)

Establishment of Hepatitis C Virus RNA-Replicating Cell Lines Possessing Ribavirin-Resistant Phenotype
por: Satoh, Shinya, et al.
Publicado: (2015)

Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity
por: Zhang, Pei, et al.
Publicado: (2009)

Ribavirin-Induced Anemia in Hepatitis C Virus Patients Undergoing Combination Therapy
por: Krishnan, Sheeja M., et al.
Publicado: (2011)

Extinction of Hepatitis C Virus by Ribavirin in Hepatoma Cells Involves Lethal Mutagenesis
por: Ortega-Prieto, Ana M., et al.
Publicado: (2013)

Modeling Ribavirin‐Induced Anemia in Patients with Chronic Hepatitis C Virus
por: Wu, LS, et al.
Publicado: (2016)

Ledipasvir/sofosbuvir and ribavirin for the treatment of ribavirin-refractory persistent hepatitis E virus infection
por: Gallacher, Jennifer, et al.
Publicado: (2023)

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
por: Akram, Madiha, et al.
Publicado: (2011)

Use of ribavirin in viruses other than hepatitis C. A review of the evidence()
por: Ramírez-Olivencia, German, et al.
Publicado: (2019)

The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis C
por: Abenavoli, Ludovico, et al.
Publicado: (2011)

Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection
por: Feld, Jordan J., et al.
Publicado: (2016)

Genetic Variability of Hepatitis C Virus before and after Combined Therapy of Interferon plus Ribavirin
por: Cuevas, José Manuel, et al.
Publicado: (2008)

Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection
por: Kuntzen, Thomas, et al.
Publicado: (2016)

Hepatitis C virus quasispecies in chronically infected children subjected to interferon–ribavirin therapy
por: Figlerowicz, Magdalena, et al.
Publicado: (2010)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection
por: Waldenström, Jesper, et al.
Publicado: (2016)

Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review
por: Mucenic, Marcos, et al.
Publicado: (2019)

Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy
por: Alhamlan, Fatimah S, et al.
Publicado: (2014)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
por: Gonçales, Fernando L, et al.
Publicado: (2010)

Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection
por: Rosenthal, Philip, et al.
Publicado: (2019)

Hepatitis C virus eradication improves immediate and delayed episodic memory in patients treated with interferon and ribavirin
por: Barbosa, Mary Ellen Dias, et al.
Publicado: (2017)

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis
por: Kim, Kyung Hoon, et al.
Publicado: (2011)

Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country
por: Hlaing, Naomi Khaing Than, et al.
Publicado: (2016)

Nucleoside analogue 2’-C-methylcytidine inhibits hepatitis E virus replication but antagonizes ribavirin
por: Qu, Changbo, et al.
Publicado: (2017)

Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection
por: Sato, Shinya, et al.
Publicado: (2019)

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
por: Cho, Hyun Chin, et al.
Publicado: (2013)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
por: Carvalho-Filho, Roberto J, et al.
Publicado: (2010)

Ritonavir Blocks Hepatitis E Virus Internalization and Clears Hepatitis E Virus In Vitro with Ribavirin
por: Primadharsini, Putu Prathiwi, et al.
Publicado: (2022)

Mutagenic Effects of Ribavirin on Hepatitis E Virus—Viral Extinction versus Selection of Fitness-Enhancing Mutations
por: Todt, Daniel, et al.
Publicado: (2016)

Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1
por: Sharafi, Heidar, et al.
Publicado: (2015)

354 Autoimmune Hepatitis Misdiagnosed as Hepatitis C Responding to Interferon/Ribavirine Therapy
por: Pijak, Michal R., et al.
Publicado: (2012)

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence
por: Poordad, Fred, et al.
Publicado: (2016)

Ribavirin Contributes to Hepatitis C Virus Suppression by Augmenting pDC Activation and Type 1 IFN Production
por: Wang, Yang, et al.
Publicado: (2015)

Negative Regulation of Hepatitis C Virus Specific Immunity Is Highly Heterogeneous and Modulated by Pegylated Interferon-Alpha/Ribavirin Therapy
por: Claassen, Mark A. A., et al.
Publicado: (2012)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
por: McEwan, Phil, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_liv9nihuid7nd935eo6ha0af5m